Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3520 ARTÍCULOS , VIENDO DEL 2341 AL 2355

Validation of an instrument to measure older adults' expectations regarding movement (ERM)

Dahodwala N, Karlawish J, Shea JA, Zubritsky C, Stern M, Mandell DS.

PLoS One. 2012;7(8):e43854. doi: 10.1371/journal.pone.0043854. Epub 2012 Aug 24.

Lingual kinematics during rapid syllable repetition in Parkinson's disease

Wong MN, Murdoch BE, Whelan BM.

Int J Lang Commun Disord. 2012 Sep-Oct;47(5):578-88. doi: 10.1111/j.1460-6984.2012.00167.x. Epub 2012 Jul 18.

Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection

Hölscher C.

CNS Drugs. 2012 Oct 1;26(10):871-82. doi: 10.2165/11635890-000000000-00000.

The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations

Tan L, Yu JT, Tan L.

J Neurol Sci. 2012 Dec 15;323(1-2):1-8. doi: 10.1016/j.jns.2012.08.005. Epub 2012 Aug 29.

Physical exercise as a possible strategy for brain protection: evidence from mitochondrial-mediated mechanisms

Marques-Aleixo I, Oliveira PJ, Moreira PI, Magalhães J, Ascensão A.

Prog Neurobiol. 2012 Nov;99(2):149-62. doi: 10.1016/j.pneurobio.2012.08.002. Epub 2012 Aug 23.

The history of the research of iron in parkinsonian substantia nigra

Friedman A, Galazka-Friedman J.

J Neural Transm (Vienna). 2012 Dec;119(12):1507-10. doi: 10.1007/s00702-012-0894-8. Epub 2012 Sep 2.

Role of prion protein aggregation in neurotoxicity

Corsaro A, Thellung S, Villa V, Nizzari M, Florio T.

Int J Mol Sci. 2012;13(7):8648-8669. doi: 10.3390/ijms13078648. Epub 2012 Jul 11.

From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors

Deftereos SN, Dodou E, Andronis C, Persidis A.

Expert Rev Clin Pharmacol. 2012 Jul;5(4):413-25. doi: 10.1586/ecp.12.29.

Neuropsychological assessment of driving safety risk in older adults with and without neurologic disease

Anderson SW, Aksan N, Dawson JD, Uc EY, Johnson AM, Rizzo M.

J Clin Exp Neuropsychol. 2012;34(9):895-905. doi: 10.1080/13803395.2011.630654. Epub 2012 Sep 3.

The combined effect of subthalamic nuclei deep brain stimulation and L-dopa increases emotion recognition in Parkinson's disease

Mondillon L, Mermillod M, Musca SC, Rieu I, Vidal T, Chambres P, Auxiette C, Dalens H, Marie Coulangeon L, Jalenques I, Lemaire JJ, Ulla M, Derost P, Marques A, Durif F.

Neuropsychologia. 2012 Oct;50(12):2869-2879. doi: 10.1016/j.neuropsychologia.2012.08.016. Epub 2012 Aug 28.

Inflammation and neurodegeneration: the story 'retolled'

Drouin-Ouellet J, Cicchetti F.

Trends Pharmacol Sci. 2012 Oct;33(10):542-51. doi: 10.1016/j.tips.2012.07.002. Epub 2012 Aug 31.

[Apathy neural bases in neurodegenerative disorders]

Robert G, Lozachmeur C, Le Jeune F, Vérin M, Drapier D.

Rev Neurol (Paris). 2012 Aug-Sep;168(8-9):605-19. doi: 10.1016/j.neurol.2012.05.005. Epub 2012 Aug 31.

Can a screening questionnaire accurately identify mild Parkinsonian signs?

Dahodwala N, Kubersky L, Siderowf A; PARS Investigators.

Neuroepidemiology. 2012;39(3-4):171-5. doi: 10.1159/000341409. Epub 2012 Aug 29.

The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial

Marquet A, Kupas K, Johne A, Astruc B, Patat A, Krösser S, Kovar A.

Clin Pharmacol Ther. 2012 Oct;92(4):450-7. doi: 10.1038/clpt.2012.128. Epub 2012 Sep 5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias